usp7 fragment (Addgene inc)
Structured Review

Usp7 Fragment, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/usp7 fragment/product/Addgene inc
Average 92 stars, based on 6 article reviews
Images
1) Product Images from "Targeted degradation of USP7 in solid cancer cells reveals disparate effects of deubiquitinase inhibition vs. acute protein depletion"
Article Title: Targeted degradation of USP7 in solid cancer cells reveals disparate effects of deubiquitinase inhibition vs. acute protein depletion
Journal: bioRxiv
doi: 10.1101/2025.07.01.662351
Figure Legend Snippet: a. Outline of this study. Comparative analysis of USP7 inhibition or degradation in PDAC and melanoma will be carried out using customized inhibitors and degraders. b. Chemical structures of previously described USP7 inhibitors as well as of NK192 (chimera derived from potent USP7 inhibitors FT671 and Compound 5) which was used as USP7 ligand for the PROTAC library synthesis. Half-maximal inhibition (IC 50 ) values were derived from data shown in panel c. NK264 represents a Biotin-functionalized variant of NK192, which was used for pulldown experiments shown in panel d. c. Ubiquitin-Rhodamine110Gly (Ub-RhoG) cleavage assay to determine inhibitory potency of compounds shown in b. Full length human USP7 was incubated with the respective compounds, the fluorogenic substrate was added and residual activity was read out through fluorescence measurements. d. Competitive pulldown experiment to assess proteome-wide specificity of NK192. Biotin-functionalized NK264 was immobilized on beads. Proteins enriched from Panc89 lysate either treated with DMSO or with NK192 (10 µM, 500x IC 50 ) were quantified by mass spectrometry.
Techniques Used: Inhibition, Derivative Assay, Variant Assay, Ubiquitin Proteomics, Cleavage Assay, Incubation, Activity Assay, Fluorescence, Mass Spectrometry
Figure Legend Snippet: a. Schematic of the synthesis of USP7-targeting degraders. Functionalized USP7 ligands (top left, pink triangle) were either coupled directly to VHL-linker conjugates (yellow triangle with grey stick, through steps A and B) or first further functionalized with linkers followed by coupling to the VHL ligand (yellow triangle, through steps A, C and D). See the Supporting Information for detailed chemical procedures. b. Chemical structures of USP7-targeting degrader library. A general structure of the PROTACs is shown on the left, consisting of a USP7 binding ligand (top) and E3 ligase binding ligand (bottom) separated by a linker. Linker attachment points to both ligands are indicated by waved lines (black: USP7, red: VHL). Linkers are shown in the table on the right. c.-d. Assessment of USP7 levels upon treatment with compounds in Panc89 cells (c) and Ma-Mel-47 cells (d). Cells were treated with 5 µM of indicated compounds for 24 h, and cell lysates were analyzed through Western blots with indicated antibodies. See the Supporting Information for uncropped blots. e. Chemical structure of NK225.
Techniques Used: Binding Assay, Western Blot
Figure Legend Snippet: a. Chemical structures of improved VHL-targeting PROTACs NK250, NK266 and non-VHL binding control compound NK245. The additional methyl groups in the VHL ligand in NK250 and NK266 (leading to enhanced VHL binding) as well as the inversed hydroxyproline stereocenter in NK245 (abrogating VHL binding) are highlighted. b. USP7 degradation assay. Panc89 cells (left) or Ma-Mel-47 cells (right) were treated with 5 µM of indicated compounds for 24 h and analyzed by Western blot. See the Supporting Information for uncropped blots. c. Assessment of USP7 degradation efficiency. Panc89 cells (left) or Ma-Mel-47 cells (right) were treated with increasing concentrations of either NK250 (left) or NK266 (right). d. Determination of degradation kinetics. Panc89 cells (left) or Ma-Mel47 cells (right) were treated with of 1 µM of NK250 (left) and NK266 (right) for indicated times. e. Degradation rescue experiment. Panc89 cells (left) or Ma-Mel47 cells (right) were pretreated for 2 h with either DMSO, NEDDylation inhibitor MLN4924 (500 nM), proteasome inhibitor Carfilzomib (CFZ, 250 nM) or VHL ligand NK249 (10 µM) followed by 1 µM of NK250 or N266 for 20 h. f. Chemical structure of VHL ligand NK249. g. Orthogonal confirmation of USP7 depletion by immune fluorescence. Panc89 cells were treated with 1 µM NK250 for 24 h before staining for USP7 (green), actin (red), and with DAPI (blue). Scale bar: 10 µm.
Techniques Used: Binding Assay, Control, Degradation Assay, Western Blot, Fluorescence, Staining
Figure Legend Snippet: a. Schematic representation of HiBiT endpoint degradation assay. b. HiBiT-based quantification of USP7 levels. MV4-11 cells stably expressing HiBiT-USP7 generated through lentiviral transduction were treated with PROTACs for either 6 or 24 h. Remaining HiBiT-USP7 could be detected through the luciferase signal using HiBiT Lytic Detection System. Data are shown as mean ± S.D. (N=3), normalized to DMSO treatment. Half-maximal degradation concentrations (DC 50 ) derived from these data are given. c. Schematic representation of a cellular ternary complex formation assay. Halotag-VHL- and NanoLuc-USP7-expressing cells are sequentially treated with Halotag-Fluorophor and PROTAC. Compound-induced proximity is read out by a bioluminescence resonance energy transfer (BRET) signal as shown, demonstrating ternary complex formation. d. Cellular ternary complex formation assay. HEK293T cells overexpressing Halotag-VHL and NanoLuc-USP7 were treated with HaloTag NanoBRET 618 Ligand for 20 h, followed by NK250 or NK266 treatment at indicated concentrations for 2 h prior BRET measurement. The determined half-maximal ternary complex formation concentration (EC 50 ) for NK250 is given. Data are shown as mean ± S.D. (N=4). mBu, milli BRET units.
Techniques Used: Degradation Assay, Stable Transfection, Expressing, Generated, Transduction, Luciferase, Derivative Assay, Tube Formation Assay, Bioluminescence Resonance Energy Transfer, Concentration Assay
Figure Legend Snippet: Proteomic analysis of Panc89 cells treated with PROTAC NK250 (a-c) or inhibitor NK192 (d-f) for indicated time points. Volcano blots report proteins identified by data-independent acquisition mass spectrometry in Panc89 cells treated with NK192 (5 µM) or NK250 (1 µM) for 6, 24 or 72 h. Proteins annotated as members of the non-canonical repressive complex 1.6 are highlighted in orange, chromatin bound E3 ligases are highlighted in black, the most upregulated proteins by USP7 inhibition in blue. g.-l. Proteomic analysis of Ma-Mel-47 cells treated with PROTAC NK266 (g-I, 1 µM) or inhibitor NK192 (j-l, 5 µM) for indicated time points.
Techniques Used: Data-independent acquisition, Mass Spectrometry, Inhibition

